It will most likely be "non inferior" to the standard of care, since that is the bar for new drugs to clear in any disease area. The issue with that designation is the FDA could compare it to stimulants or to the non-stimulant atomextine, which like Viloxazine is a norepinephrine reuptake inhibitor.

Atomoxetine was preferentially used in those cases with added anxiety, since it was found to have anxiolytic effects. Stimulants were sometimes not recommended for anxious patients, since they might contribute to anxiety and sleeplessness for some kids.